Contents:

TABLE OF CONTENTS EXECUTIVE SUMMARY INTRODUCTION ER +VE BREAST CANCER Targeted therapies: In the beginning there was tamoxifen Current standard of care for ER +ve breast cancer New challenges for Nolvadex as aromatase inhibitors gain approval for first line treatment Key trials results peek physician interests in aromatase inhibitors Commercial implications: Is Nolvadex' dominance drawing to a close? Hormonal treatment for premenopausal women, are LHRH agonists a viable alternative to oopherectomy? Does goserelin offer a low toxicity alternative to CMF? Conclusions and commercial implications ER -VE BREAST CANCER Current standard of care ER -ve breast cancer: An expanding role envisioned for the Taxanes Evidence from US Intergroup's research, but European physicians remain cautious Conclusions and implications Second-line treatment for metastatic breast cancer: What happens when anthracyclines and taxanes fail? Oral vinorelbine: an improved option for advanced breast cancer? TARGETED THERAPIES - THE FUTURE OF BREAST CANCER TREATMENT? New directions in breast cancer research The rise and rise of Herceptin Herceptin, the story so far Potential as a combination therapy? Phase III trials; compromises and controversies Commercial implications: Can Herceptin succeed in Europe? Could HER2 overexpression be a predictive factor for other forms of treatment? Tyrosine Kinase induction pathway: the next frontier in breast cancer treatment Novel drugs targetting the EGFR pathway 3rd generation aromatase inhibitors.....is Faslodex set to dominate breast cancer treatment? OVERALL CONCLUSIONS Hanging fire until ASCO, but still a key conference for Europe About Datamonitor